DHB vs Testosterone
Limited Research vs FDA Approved
synergistic Researched · 95% A testosterone base is essential when running DHB. DHB suppresses endogenous testosterone production and does not aromatize, so without exogenous testosterone, estradiol levels will crash, leading to low-estrogen symptoms including joint pain, flat mood, low libido, and adverse lipid changes. Typical ratios are 1:4 to 1:2 DHB-to-testosterone (e.g., 200-400 mg DHB with 500-800 mg testosterone per week). The testosterone provides the estrogenic support that DHB cannot.
Molecular Data
DHB Testosterone
Weight 288.43 Da (base) 288.42 Da (base)
Half-life ~7-9 days (cypionate ester) ~8 days (cypionate)
Type 5-alpha reduced boldenone derivative (C19H28O2) Steroid hormone (C19H28O2)
Key Benefits
DHB
01 High anabolic potency (approximately 200:100 anabolic-to-androgenic ratio) promoting lean, quality muscle gains
02 No aromatization to estrogen, eliminating water retention, bloating, and gynecomastia risk from the compound itself
03 Produces dry, lean aesthetic gains comparable to Primobolan at a fraction of the cost
04 Does not convert to DHT or other more androgenic metabolites via 5-alpha reductase, as it is already 5-alpha reduced
05 Can be stacked with testosterone without significantly complicating estrogen management
06 Moderate androgenic activity supports strength gains without excessive androgenic side effects in most users
Testosterone
01 Restoration of normal testosterone levels in hypogonadal men
02 Increased lean muscle mass and strength
03 Improved bone mineral density and reduced fracture risk
04 Enhanced libido, sexual function, and erectile quality
05 Improved mood, energy, motivation, and cognitive clarity
06 Reduction in body fat percentage, particularly visceral fat
07 Increased red blood cell production and oxygen-carrying capacity
08 Improved insulin sensitivity and metabolic health markers
Dosing Protocols
DHB
200-400 mg/week / 2-3x per week (cypionate)
Lean Bulk - Moderate 200-300 mg/week 2-3x per week (cypionate)
Lean Bulk - Standard 300-400 mg/week 2-3x per week (cypionate)
Cutting / Recomposition 200-300 mg/week 2-3x per week (cypionate)
Testosterone
100-200 mg/week (TRT) / 1-2x per week (injectable)
TRT - Standard Replacement 100-200 mg/week 1-2x per week
TRT - Conservative Start 80-100 mg/week 2x per week (40-50 mg per injection)
TRT - Propionate Protocol 25-50 mg every other day Every other day or 3x per week
Performance Enhancement - Moderate 300-500 mg/week 2x per week
Performance Enhancement - Advanced 500-750 mg/week 2-3x per week
Side Effects
DHB
Severe post-injection pain (PIP) -- the defining side effect of DHB, reported by the majority of users regardless of concentration, carrier oil, or injection technique. Pain typically begins 12-48 hours post-injection and can last 3-7 days, sometimes accompanied by redness, swelling, and warmth at the injection site.
Suppression of endogenous testosterone production (profoundly suppressive, as with all AAS)
Mild to moderate acne and oily skin in predisposed individuals
Mild hair thinning in genetically predisposed individuals
Mild liver stress (elevated ALT/AST reported even with injectable administration, potentially related to carrier solvents or the compound's metabolic pathway)
Testosterone
Acne and oily skin (increased sebum production via DHT)
Water retention and bloating (estrogen-mediated)
Mild mood changes (irritability, increased assertiveness)
Increased hematocrit and hemoglobin (erythrocytosis)
Testicular atrophy (suppression of LH/FSH from exogenous testosterone)
Injection site pain, redness, or irritation
Increased body hair growth
Mild elevation in blood pressure
Contraindications
Hepatic impairment or liver disease (DHB has mild hepatotoxic potential)
Cardiovascular disease or history of thromboembolic events
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Known hypersensitivity to DHB, cypionate ester, or common carrier solvents (guaiacol, ethyl oleate)
Pregnancy or potential for pregnancy (Category X)
Pre-existing injection site complications or chronic inflammatory conditions at common injection sites
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled severe heart failure
Untreated severe obstructive sleep apnea
Desire for near-term fertility (without concurrent HCG/FSH)
Pregnancy or potential exposure to pregnant women (Category X)
Hypersensitivity to testosterone or any formulation components
Research Evidence
DHB Testosterone
Status Limited Research FDA Approved
References 4 studies 5 studies
Latest January 2017 June 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.